Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours - Full Text View

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00108017

Purpose

This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.

Condition	Intervention	Phase
Glaucoma Ocular Hypertension	Drug: MK0507A, dorzolamide hydrochloride (+) timolol maleate Drug: Comparator: timolol maleate Drug: Duration of Treatment: Part 1) 6 wk timolol maleate run in Drug: Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	Randomized, Multicenter, Dbl-Masked, Parallel Study Evaluating the 24 Hr. Diurnal Ocular Hypotensive Effect of 2% Dorzolamide Hydrochloride/0.5% Timolol Maleate Combo. Ophthalmic Sol. in Patients w/ Open Angle Glaucoma or Ocular Hypertension

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure

Drug Information available for: Timolol Timolol maleate Dorzolamide Dorzolamide hydrochloride

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:

24 hour diurnal IOP reduction after 8 weeks of treatment [ Time Frame: After 8 weeks of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

IOP reduction a) from baseline at 6 weeks; b) comparison with timolol; c) comparison day versus night [ Time Frame: At 6 weeks ] [ Designated as safety issue: No ]

Enrollment:	330
Study Start Date:	July 2005

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with glaucoma or ocular hypertension

Exclusion Criteria:

Other eye conditions
Poor vision
Recent eye surgery
Use of contact lenses
Nursing or pregnant women
Use of some other selected medications
Drug or alcohol abuse
Asthma
Slow heart beat
Allergy or previous reaction to study drugs

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00108017

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Publications:

Feldman RM, Stewart RH, Stewart WC, Jia G, Smugar SS, Galet VA. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma. Curr Med Res Opin. 2008 Jul 14; [Epub ahead of print]

Olander KW, Galet VA, Jia G, Smugar SS, Stewart WC. Relationship Between Visual Field Severity and Response to Fixed Combination Dorzolamide/Timolol or Timolol Alone. J Ocul Pharmacol Ther. 2009 May 14; [Epub ahead of print]

Responsible Party:	Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier:	NCT00108017 History of Changes
Other Study ID Numbers:	2005_021, MK0507A-137
Study First Received:	April 12, 2005
Last Updated:	January 27, 2010
Health Authority:	United States: Food and Drug Administration

Keywords provided by Merck:

Ocular hypertension (excessive pressure in the eye)

Additional relevant MeSH terms:

Glaucoma
Hypertension
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Timolol
Dorzolamide
Maleic acid
Adrenergic beta-Antagonists
Adrenergic Antagonists

Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Antihypertensive Agents
Enzyme Inhibitors
Carbonic Anhydrase Inhibitors

ClinicalTrials.gov processed this record on February 08, 2012